Adaptive Biotechnologies (ADPT) Change in Receivables (2018 - 2026)

Adaptive Biotechnologies has disclosed Change in Receivables across 9 years of filings, most recently posting -$2.0 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$2.0 million, down 209.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (up 204.11% YoY), and the FY2025 annual result was $8.6 million, up 130.93% from the prior year.
• Change in Receivables came in at -$2.0 million for Q1 2026 at Adaptive Biotechnologies, down from $5.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $13.5 million in Q4 2022 to a low of -$9.1 million in Q1 2023.
• The 5-year median for Change in Receivables is $1.2 million (2022), against an average of $1.8 million.
• Across the five-year window, Change in Receivables jumped 4606.97% in 2022 and slumped 1132.37% in 2024, its largest moves.
• Adaptive Biotechnologies' Change in Receivables stood at $13.5 million in 2022, then slumped by 49.91% to $6.8 million in 2023, then tumbled by 86.71% to $899000.0 in 2024, then jumped by 516.69% to $5.5 million in 2025, then slumped by 136.98% to -$2.0 million in 2026.
• The last three Change in Receivables figures came in at -$2.0 million (Q1 2026), $5.5 million (Q4 2025), and $536000.0 (Q3 2025), per Business Quant data.